Advertisement
UK markets close in 3 hours 52 minutes

  • FTSE 100

    8,120.81
    +41.95 (+0.52%)
     

  • FTSE 250

    19,815.48
    +213.50 (+1.09%)
     

  • AIM

    755.42
    +2.30 (+0.31%)
     

  • GBP/EUR

    1.1666
    +0.0010 (+0.08%)
     

  • GBP/USD

    1.2516
    +0.0005 (+0.04%)
     

  • Bitcoin GBP

    51,252.18
    +274.18 (+0.54%)
     

  • CMC Crypto 200

    1,386.24
    -10.30 (-0.74%)
     

  • S&P 500

    5,048.42
    -23.21 (-0.46%)
     

  • DOW

    38,085.80
    -375.12 (-0.98%)
     

  • CRUDE OIL

    84.12
    +0.55 (+0.66%)
     

  • GOLD FUTURES

    2,359.20
    +16.70 (+0.71%)
     

  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     

  • HANG SENG

    17,651.15
    +366.61 (+2.12%)
     

  • DAX

    18,061.83
    +144.55 (+0.81%)
     

  • CAC 40

    8,048.07
    +31.42 (+0.39%)
     
PROPERTY:

9 luxury homes to consider if money is no object

Ever thought about what a multimillion pound budget would buy you?

How Did Amgen’s Enbrel, Nplate, and Vectibix Perform in 3Q17?

Daniel Collins

In 3Q17, Amgen’s (AMGN) Enbrel generated revenues of around $1.36 billion, which reflected ~6% growth on year-over-year (or YoY) basis and ~7% growth on a quarter-over-quarter basis.

Continue reading